-
J. Neurol. Neurosurg. Psychiatr. · Feb 2016
Serum neurofilament light chain levels are increased in patients with a clinically isolated syndrome.
- Giulio Disanto, Rocco Adiutori, Ruth Dobson, Vittorio Martinelli, Gloria Dalla Costa, Tessel Runia, Evgeniy Evdoshenko, Eric Thouvenot, Maria Trojano, Niklas Norgren, Charlotte Teunissen, Ludwig Kappos, Ga... more
- Queen Mary University of London, Blizard Institute, Barts and The London School of Medicine and Dentistry, London, UK Neurocentre of Southern Switzerland, Ospedale Civico, Lugano, Switzerland.
- J. Neurol. Neurosurg. Psychiatr. 2016 Feb 1; 87 (2): 126-9.
BackgroundNeurofilament light chain (NfL) represents a promising biomarker for axonal injury. We present the first exploratory study on serum NfL in patients with a clinically isolated syndrome (CIS) and healthy controls.MethodsWe investigated serum NfL levels in 100 patients with CIS with a short conversion interval to clinically definite multiple sclerosis (MS) (fast converters (FC), median (IQR) conversion time: 110 days (79-139)); 98 patients with non-converting CIS (non-converters (NC), follow-up: 6.5 years (5.3-7.9)); and 92 healthy controls.ResultsNfL levels were higher in FC (24.1 pg/mL (13.5-51.8)) and NC (19.3 pg/mL (13.6-35.2)) than in healthy controls (7.9 pg/mL (5.6-17.2)) (OR=5.85; 95% CI 2.63 to 13.02; p = 1.5 × 10(-5) and OR = 7.03; 95% CI 2.85 to 17.34; p = 2.3 × 10(-5), respectively). When grouping FC and NC, increased serum NfL concentration was also associated with increasing numbers of T2 hyperintense MRI lesions (OR = 2.36; 95% CI 1.21 to 4.59; p = 0.011), gadolinium-enhancing lesions (OR = 2.69; 95% CI 1.13 to 6.41; p=0.026) and higher disability scores (OR = 2.54; 95% CI 1.21 to 5.31; p = 0.013) at CIS diagnosis.ConclusionsIf replicated in future studies, serum NfL may represent a reliable and easily accessible biomarker of early axonal damage in CIS and MS.Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/
Notes